Compare MRAM & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRAM | MDWD |
|---|---|---|
| Founded | 2008 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 224.6M |
| IPO Year | 2016 | 2013 |
| Metric | MRAM | MDWD |
|---|---|---|
| Price | $9.52 | $17.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $14.00 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 442.2K | 71.5K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,417,000.00 | N/A |
| Revenue This Year | $10.87 | $57.63 |
| Revenue Next Year | $8.33 | $26.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.51 | N/A |
| 52 Week Low | $4.34 | $14.14 |
| 52 Week High | $17.24 | $22.51 |
| Indicator | MRAM | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 50.71 |
| Support Level | $8.42 | $17.10 |
| Resistance Level | $9.74 | $18.58 |
| Average True Range (ATR) | 0.57 | 0.56 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 31.23 | 72.59 |
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.